Memorial Sloan Kettering Cancer Center (MSK) has been fighting cancer cells with immune cells for more than 120 years. Researchers across disciplines including immunologists, geneticists and cell biologists work together to make groundbreaking developments. They create powerful immune therapies, focusing on checkpoint inhibitors and CAR-T cell therapy, to treat various forms of advanced cancer. PICI researchers at MSK push the boundaries in cancer research – not only to improve existing immunotherapies but open doors to new ones. Jedd Wolchok, MD, PhD | Director Marcel van den Brink, MD, PhD | Co-Director All Investigators Related Point of View Guest Post: PICI Catalyzes Scientific Innovation Clinical Trial The AMADEUS Trial Clinical Trial The McGRAW Trial Clinical Trial The PRINCE Trial Announcement, Press Release Funding the Future of Cancer Research Announcement, Press Release Alliance Aims to Develop Next-Gen Cancer Therapies Announcement, Press Release Biomarkers May Predict Better Treatment Options Announcement, Press Release First Patients Dosed in Pancreatic Platform Trial Partner Highlight Connecting Patients with Innovative Immunotherapies